Assessing Blood Pressure Responses to Noncardiovascular Drugs: The Beneficial Role of Ambulatory Blood Pressure Monitoring

Journal of Clinical Hypertension

Volumn 15, Issue 1, 2013, Pages 55-62

  O'Brien, Eoin ^a   Turner, J Rick ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BARBITAL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISULFIRAM; IBUPROFEN; LOPINAVIR; METFORMIN; NAPHAZOLINE; OXYMETAZOLINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PROGESTERONE; PSEUDOEPHEDRINE; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; RITONAVIR; SODIUM; SUNITINIB; TETRYZOLINE; UNINDEXED DRUG; VASCULAR TARGETING AGENT;

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; COMPUTER; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENZYME INHIBITION; FINANCE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MORBIDITY; NONHUMAN; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; PULSE WAVE; QT PROLONGATION; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; HUMANS;

EID: 84871935629     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12023     Document Type: Article

References (65)

1. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125:14-22.
2. Martins LC, Ferreira-Melo SE, Sabha M, et al.Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers. Blood Press. 2005;18:255-260.
3. Bamias A, Manios E, Karadimou A, et al.The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer. 2011;47:1660-1668.
4. Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril. 2009;91:2527-2536.
5. Pilecki T, Paczek L, Senatorski G, et al.Effect of immunosuppressive treatment on diurnal profile of blood pressure. Pol Merkur Lekarski. 2002;13:37-40.
6. Wasilewska A, Zoch-Zwierz W, Tomaszewska B, Tenderenda E. The effect of cyclosporine A in steroid-dependent nephrotic syndrome in children. Pol Merkur Lekarski. 2005;18:168-172.
7. Sudano I, Flammer AJ, Periat D, et al.Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122:1789-1796.
8. Wright JT, McKenney JM, Lehany AM, et al.The effect of high-dose short-term ibuprofen on antihypertensive control with hydrochlorothiazide. Clin Pharmacol Ther. 1989;46:440-444.
9. Kostka-Jeziorny K, Uruski P, Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press. 2011;20:104-110.
10. Magen E, Viskoper JR, Mishral J, et al.Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. J Hum Hypertens. 2005;19:667-673.
11. Sumino H, Ichikawa S, Kumakura H, et al.Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women. Hypertens Res. 2003;26:369-376.
12. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:92-95.
13. Gürsoy A, Erdoǧan MF, Cin MO, et al.Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension. Endocr Pract. 2005;11:308-312.
14. Satin LZ, Gutstein DE. Meeting report: 5th annual cardiovascular risk assessment summit. Drug Inf J. 2011;45:535-540.
15. Turner JR. Cardiovascular safety watch column. J Clin Stud. 2011;3:10.
16. O'Brien E. Why ABPM should be mandatory in all trial of blood pressure-lowering drugs. Drug Inf J. 2011;45:233-239.
17. O'Brien E. The value of 24-hour blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. Hot Topics Hypertens. 2011;4:7-23.
18. Stolarz-Skrzypek K, Thijs L, Wizner B, et al.From pioneering to implementing automated blood pressure measurement in clinical practice: Thomas Pickering's legacy. Blood Press Monit. 2010;15:72-81.
19. Owens P, Atkins N, O'Brien E. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. Hypertension. 1999;34:267-272.
20. O'Brien E. First Thomas Pickering Memorial Lecture: ambulatory blood pressure measurement is essential for the management of hypertension. J Clin Hypertens (Greenwich). 2012; doi: 10.1111/j.1751-7176.2012.00698.
21. O'Brien E. The circadian nuances of hypertension: a reappraisal of 24-h ambulatory blood pressure measurement in clinical practice. Ir J Med Sci. 2007;176:55-63.
22. O'Brien E. 24-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J Int Med. 2011;269:478-495.
23. Yusuf S, Sleight P, Pogue J, et al.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
24. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
25. Williams B. The renin-angiotensin system and cardiovascular disease: hope or hype?J Renin Angiotensin Aldosterone Syst. 2000;1:142-146.
26. Svensson P, de Faire U, Sleight P, et al.Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:E28-E32.
27. Moutsatsos GD. More hype than HOPE. Hypertension. 2003;41:e4.
28. Stockbridge S. Letter to the Editor: ABPM part of FDA reviews. Drug Inf J. 2011;45:567.
29. Dolan E, Stanton A, Thijs L, et al.Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. The Dublin Outcome Study. Hypertension. 2005;46:156-161.
30. Sega R, Facchetti R, Bombelli M, et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population. Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-1783.
31. Mancia G, Bombelli M, Facchetti R, et al.Long-term prognostic value of blood pressure variability in the general population. Results of the Pressioni Arteriose Monitorate a Loro Associazioni study. Hypertension. 2007;49:1265-1270.
32. Ben-Dov IZ, Kark JD, Ben-Ishay D, et al.Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension. 2007;49:1235-1241.
33. Fagard RH, Celis H, Thijs L, et al.Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61.
34. Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med. 2009;169:874-880.
35. Fan HQ, Li Y, Thijs L, et al.Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036-2045.
36. O'Brien E. Is the case for ABPM as a routine investigation in clinical practice not overwhelming?Hypertension. 2007;50:284-286.
37. Logan AG. Ambulatory blood pressure monitoring: it's time to move on!J Hypertens. 2010;28:2000-2002.
38. Rocco MB, Barry J, Campbell S, et al.Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation. 1987;75:395-400.
39. Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke. 1998;29:992-996.
40. Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. Am J Hypertens. 2005;18:149-151.
41. Rothwell PM, Howard SC, Dolan E, et al.Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.
42. Rothwell PM, Howard SC, Dolan E, et al.Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469-480.
43. Dolan E, O'Brien E. Blood pressure variability: clarity for clinical practice. Hypertension. 2010;56:179-181.
44. ICH Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf. Accessed June 20, 2012.
45. ICH Guideline E14 Questions & Answers Document, Revision 1. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions & answers. 2012. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R1_step4.pdf. Accessed June 20, 2012.
46. Satin LZ, Durham TA, Turner JR. Assessing a drug's proarrhythmic liability: an overview of computer simulation modeling, nonclinical assays, and the Thorough QT/QTc Study. Drug Inf J. 2011;45:357-375.
47. Turner JR. Integrated cardiovascular safety: employing a three-component risk exclusion model in the assessment of investigational drugs. Appl Clin Trials. 2010;19: June issue:76-79.
48. Highlights of prescribing information for crizotinib. http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed August 9, 2012.
49. Highlights of prescribing information for vemurafenib. http://www.gene.com/gene/news/news-events/zelboraf/pi.pdf. Accessed August 9, 2012.
50. Rock EP, Finkle J, Fingert HJ, et al.Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J. 2009;157:827-836, 836.e1.
51. Levitan BS, Andrews EB, Gilsenan A, et al.Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011;89:217-224.
52. Noel R, Hermann R, Levitan B, et al.Application of the Benefit-Risk Action Team (BRAT) Framework in Pharmaceutical R&D: results from a pilot program. Drug Inf J. 2012; doi:10.1177/0092861512458908.
53. Krucoff M. Focus on the cardiac safety research consortium. Drug Inf J. 2011;45:241-244.
54. Krakoff LR. Cost-effectiveness of ambulatory blood pressure: a reanalysis. Hypertension. 2006;47:29-34.
55. White WB. Expanding the use of ambulatory blood pressure monitoring for the diagnosis and management of patients with hypertension. Hypertension. 2006;47:14-15.
56. O'Brien E. Ambulatory blood pressure measurement. The case for implementation in primary care. Hypertension. 2008;51:1435-1441.
57. National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011. www.nice.org.uk/guidance/CG127. Accessed August 9, 2012.
58. Lovibond K, Jowett S, Barton P, et al.Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219-1230.
59. White WB, Maraka S. Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?Curr Hypertens Rep. 2012;14:366-373.
60. Campbell P, Ghuman N, Wakefield D, et al.Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly. J Hum Hypertens. 2010;24:749-754.
61. White WB. "The nighttime might be the right time" for cardiovascular event prediction. Hypertension. 2012;60:8-9.
62. White WB. The risk of waking-up: impact of the morning surge in blood pressure. Hypertension. 2010;55:835-837.
63. O'Brien E, Pickering T, Asmar R, et al.International protocol for validation of blood pressure measuring devices in adults. Blood Press Monit. 2002;7:3-17.
64. O'Brien E, Atkins N, Stergiou G, et al.European Society of Hypertension International Protocol for the validation of blood pressure measuring devices in adults. 2010 Revision. Blood Press Monit. 2010;15:23-38.
65. Stergiou G, Karpettas N, Atkins N, O'Brien E. European Society of Hypertension International Protocol for the validation of blood pressure monitors: a critical review of its application and rationale for revision. Blood Press Monit. 2010;15:39-48.